Oxford Finance served as co-lender and documentation agent in the closing of a $35 million term loan and a $15 revolving line of credit for Superior Biologics. Funds will support a recapitalization and refinancing of existing debt for the company.
“Oxford has a strong reputation in the healthcare lending marketplace,” said Mark A. Kovinsky, chief executive officer for Superior Biologics. “They delivered as promised and were critical to helping us achieve our business objectives with this credit facility.”
Superior Biologics is a home infusion and specialty pharmacy provider, offering services to pediatric and adult populations suffering from chronic illnesses.
Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide.